Recent Advances in Intravesical Drug/Gene Delivery

详细信息    查看全文

• 作者：Pradeep Tyagi ; Pao-Chu Wu ; Michael Chancellor ; Naoki Yoshimura ; Leaf Huang
• 刊名：Molecular Pharmaceutics
• 出版年：2006
• 出版时间：August 2006
• 年：2006
• 卷：3
• 期：4
• 页码：369 - 379
• 全文大小：163K
• 年卷期：v.3,no.4(August 2006)
• ISSN：1543-8392

文摘

Targeting of drugs administered systemically relies on the higher affinity of ligandsfor specific receptors to obtain selectivity in drug response. However, achieving the same goalinside the bladder is much easier with an intelligent pharmaceutical approach that restricts drugeffects by exploiting the pelvic anatomical architecture of the human body. This regional therapyinvolves placement of drugs directly into the bladder through a urethral catheter. It is obviousthat drug administration by this route holds advantage in chemotherapy of superficial bladdercancer, and it has now become the most widely used treatment modality for this ailment. Inrecent years, the intravesical route has also been exploited either as an adjunct to an oral regimenor as a second-line treatment for neurogenic bladder. (Lamm, D. L.; Griffith, J. G. Semin. Urol.1992, 10, 39-44. Igawa, Y.; Satoh, T.; Mizusawa, H.; Seki, S.; Kato, H.; Ishizuka, O.; Nishizawa,O. BJU Int. 2003, 91, 637-641.) Instillation of DNA via this route using different vectors hasbeen able to restrict the transgene expression in organs other than bladder. The present reviewarticle will discuss the shortcomings of the current options available for intravesical drug delivery(IDD) and lay a perspective for future developments in this field.